Yunkang Group Limited (“Yunkang” or the “Group”; Stock Code: 2325), a prominent medical operation companies in China, has actually revealed its interim outcomes for the 6 months ended 30 June 2025 (the “Reporting Period”. The Group embraced “one horizontal, one vertical” as its core service method: horizontally, it extended a lean management system to advance multi-mode partnership amongst medical organization alliances; vertically, it concentrated on specialty-specific development in medical diagnostics to fast-track the translation and application of brand-new innovations and items. The Group leveraged AI to boost the thorough services for medical organization alliances, promoted the useful application of AI in health care situations, and continually reinforced the worth of empowering medical practices, showing strong functional strength.
In the very first half of 2025, due to numerous aspects, consisting of the centralized drug-procurement program, expense controls of medical insurance coverage, and strong market competitors, the Group’s short-term outcomes did not fulfill expectations. The Group stayed dedicated to item and company design development, and additional improved the systems and procedures of its functional management. By sticking to lean operations, the general efficiency has actually accomplished substantial enhancements. Throughout the Reporting Period, the Group’s gross revenue margin reached around 34.0%, representing an enhancement of around 4.4% over the general gross earnings margin for 2024. The bottom line totaled up to RMB55.4 million, a considerable reduction of 56.1% compared to the exact same duration in 2015. The joint building organization stayed the Group’s biggest company section, which tape-recorded the income of RMB180.3 million, representing 57.6% of the overall income, increased by around 9.6% as compared to the exact same duration in 2015, attaining substantial results in empowering medical alliance customers through extensive services, leading the way for the Group’s long-lasting top quality development. Throughout the Reporting Period, the Group’s diagnostic screening services taped income of RMB313.2 million
Gradually carrying out “one horizontal, one vertical” method, with noteworthy accomplishments in hospital-enterprise collaborations
“One horizontal” —- Extending lean management system to deepen varied types of partnership within medical organization alliances
Yunkang has actually been devoted to establishing an ingenious service mode for the joint building and construction of medical organization alliances including “professionalism as the structure, standardization as the core, digital intelligence as the ways, synergization as the objective”. Throughout the Reporting Period, the Group supplied almost 450 alliance customers with multi-scenario options customized to various scientific requirements, consisting of AI+ digital intelligence services for medical organization alliances, thorough partnerships with medical labs, options for regional/pathology centers and accuracy medication center, and specialty-based services for alliance advancement, to name a few multi-model partnership services. By leveraging Yunkang’s strengths, the Group helped health care organizations at all levels in improving service abilities and broadening service protection, developed a hierarchical and collaborated health care service system, and promoted the advancement of local hierarchical medical diagnosis and treatment services.
Throughout the Reporting Period, in spite of progressively strong market competitors, the Group preserved strong development in the joint building and construction organization through constant deep partnership with leading healthcare facilities and community and county-level health centers, even more combining its competitive benefit.
“One vertical” —- Joint development platform for diagnostic screening acts as strong chauffeur for R&D
The Group has actually constantly concentrated on “medical requirements”, continually enhancing hospital-enterprise cooperation and pioneering the facility of a joint development platform for diagnostic screening, driving company growth and item competitiveness. Throughout the Reporting Period, the Group created joint diagnostic development collaborations with lots of top-tier medical organizations nationwide, providing a portfolio of screening items attending to numerous transmittable syndromes, consisting of breathing system infections, main nerve system infections, urinary system infections, gynecological infections, and tuberculosis, in addition to hereditary screening items for individualized medication. Jointly, these ingenious items have actually served almost 300 customers throughout the nation, and accomplished continual development in screening income.
Throughout the Reporting Period, Yunkang and Guangdong Provincial People’s Hospital successively introduced a series of brand-new panel items covering breathing system infections, main nerve system infections, and intrusive fungal infections, effectively developing a standardized incubation design for domestic hospital-enterprise research study development and translation, in addition to a “1+N” medical examination partnership network. Throughout the procedure of clinical and technological development, both celebrations have actually gotten abundant scientific experience. With the active participation and continual efforts of lots of domestic diagnostic specialists and scholars, they created the Expert Consensus on the Application of tNGS for Clinical Standardization, which was released throughout the Reporting Period in Chinese Journal of Laboratory Medicine, a leading journal in China’s diagnostic field. Throughout the Reporting Period, Yunkang likewise kept close partnership with the First Affiliated Hospital of Guangzhou Medical University, among China’s top-tier medical facilities, and effectively established a urinary tNGS item, advancing the medical practice of accuracy medical diagnosis and treatment for urinary system infections. Concurrently, Yunkang partnered with the First Affiliated Hospital of Jinan University to develop a “university-hospital-enterprise joint development platform” and bred and run the “development task of psychiatric drug hereditary screening”, which has actually effectively yielded hereditary screening items for antidepressants, anti-anxiety drugs, and sedative-hypnotics.
AI empowers multi-modal services for medical organization alliances, enhancing quality and performance to deepen customer service
Throughout the Reporting Period, Yunkang totally utilized DeepSeek and accomplished digital implementation throughout its platforms. On the core principles of “AI+” and “accuracy diagnostics”, Yunkang thoroughly used synthetic intelligence innovation throughout the multi-technology platforms of its medical labs. Taking the thorough combination of AI innovation with Yunkang pathology medical diagnosis platform as an example, the per-slide performance of AI-empowered diagnostic was constantly enhanced, accomplishing synchronised enhancements in intelligence, performance, and quality. Through the implementation of smart applications, Yunkang understood wise online client services and the effective evaluation of outcomes and reports, which completely structured diagnostic service procedures and enhanced experience and complete satisfaction of its customer services. In the procedure of collectively establishing brand-new innovations and items through hospital-enterprise R&D, Yunkang’s AI innovation empowered item development and R&D throughout several elements, consisting of bioinformatics analysis, report analysis, illness threat evaluation, and advancement and translation of unique items, by leveraging the effective information analysis, modeling, and predictive abilities of massive AI designs. This has actually sped up the medical application.
Especially, Yunkang revealed its medical AI design “ZhiYun” established in partnership with Runda Medical and Huawei, covering the whole medical workflow from pre-diagnosis to medical diagnosis and post-diagnosis. It will offer more effective and practical assistance and experience throughout all phases of scientific medical services. Yunkang signed a tactical cooperation contract with Runda Medical to enhance extensive cooperation throughout the commercial communities in “AI + IVD + health care services”, collectively promoting the advancement and application of massive AI designs in the medical field, and offering customers with digital-intelligence health care options. In the future, “ZhiYun”, the medical AI design, will be piloted in Yunkang’s health care partners and slowly presented nationwide, to enhance quality and effectiveness of medical organization alliance operations.
Future potential customers
2025 marks the last lap for executing the 14th Five-Year Plan. China has actually sped up the capability growth of premium health care resources and their extension to lower-tier markets, leading to a more well balanced local circulation. The nation has actually likewise sped up the advancement of medical organization alliances and driven their upgrade from “structure structure” to “top quality operation”. Medical treatment is likewise moving from “broad-spectrum treatments” to “accuracy medication”, with the development capacity of the market continuing to be understood. At the exact same time, AI innovation has actually continued to empower hierarchical medical diagnosis and treatment services, and the market is welcoming brand-new development chances. Looking ahead, Yunkang will continue to equal market advancement patterns and line up with nationwide policies, even more reinforcing the worth of empowering medical practices, and constantly checking out the “item development + organization development” dual-pronged design to speed up organization advancement, deeply empower medical screening services, and benefit more locals.
Yunkang Group Limited (Stock Code: 2325)
Yunkang Group is a prominent medical operation company in China, which began to supply standardized medical diagnostic services to medical organizations at all levels as early as 2008. Leveraging its own expert diagnostic abilities and the across the country service network of incorporated health care systems, Yunkang has actually slowly grown to end up being a medical operation service platform. Yunkang is a medical operation service supplier in China providing a complete suite of diagnostic screening services which are diagnostic outsourcing services and diagnostic screening services for medical organization alliances. Yunkang offers diagnostic services through on-site diagnostic centers to collective medical facilities in the incorporated health care systems in China and helps them in enhancing their scientific medical diagnosis abilities through co-developing diagnostic. As of today, Yunkang has actually effectively supplied expert services to almost 450 on-site diagnostic. Since June 30, 2025, the health centers we teamed up with lay throughout 31 provinces and towns in China.
Subject: Press release summary
